Medicare Part B And Accelerated Approvals: MedPAC Mulls Use Of CED Versus Payment Caps

Medicare advisory panel discusses ongoing issues around launch prices that were not addressed by the government price controls targeting older drugs enacted as part of the Inflation Reduction Act.

Proposed Policy Would Allow Medicare To Essentially Limit Launch Prices • Source: Shutterstock

The Medicare Payment Advisory Commission is rethinking how Medicare Part B should manage high-cost drugs approved through the US Food and Drug Administration’s accelerated approval pathway, informed by the Centers for Medicare and Medicaid Services’ recent experience with imposing coverage with evidence development (CED) requirements on such drugs.

MedPAC recommended in its June report that CMS should combine CED with Medicare payment caps to lower costs for certain...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet